Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.

Anticancer research - 1 Oct 2023

Kataoka Masahiro, Kitazawa Masato, Nakamura Satoshi, Koyama Makoto, Yamamoto Yuta, Miyazaki Satoru, Hondo Nao, Tanaka Hirokazu, Soejima Yuji

Abstract excerpt

BACKGROUND/AIM: Kirsten Rat Sarcoma viral oncogene homolog (KRAS) has remained undruggable for decades. KRAS has predominantly been used to evaluate the applicability of anti-Epidermal Growth Factor Receptor (EGFR) antibody drugs. However, various KRAS inhibitors have recently emerged. Unfortunately, KRAS inhibitors have not been effective against colorectal cancer. Therefore, this study aimed to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Caco-2 Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37772552
DOI: 10.21873/anticanres.16629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.PMID 37772552Read ↗

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read ↗

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.Semantic proximity Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Targeting the PI3K signaling pathway in KRAS mutant colon cancer.Semantic proximity Read ↗

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancerSemantic proximity Read ↗

Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.Semantic proximity Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Semantic proximity Read ↗

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.